KEGG   DRUG: MepolizumabHelp
Entry
D04923                      Drug                                   

Name
Mepolizumab (USAN/INN);
Mepolizumab (genetical recombination) (JAN);
Nucala (TN)
Product
Remark
Therapeutic category: 
ATC code: 
Activity
Immunomodulator [monoclonal antibody]
Comment
humanized monoclonal antibody
Target
interleukin 5 (IL-5) [HSA:3567] [KO:K05428]
  Pathway
Cytokine-cytokine receptor interaction
Jak-STAT signaling pathway
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC06 Mepolizumab
      D04923  Mepolizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  22  Respiratory organ agents
   229  Miscellaneous
    2290  Miscellaneous
     D04923  Mepolizumab (USAN/INN); Mepolizumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokines
  Class I cytokines
   IL-5
    Mepolizumab
     D04923  Mepolizumab (USAN/INN)
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D04923
BRITE hierarchy
Other DBs
CAS: 
196078-29-2
PubChem: 

» Japanese version   » Back

DBGET integrated database retrieval system